{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:46:12Z","timestamp":1772142372852,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016\u201002362"],"award-info":[{"award-number":["2016\u201002362"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Antipsychotics may increase serum prolactin, which has particularly been observed with risperidone. Further, hyperprolactinemia has been linked to osteoporosis\u2010related fractures. Therefore, we investigated fracture risk in a nationwide cohort exposed to antipsychotics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Swedish registers were used to identify adults with two consecutive dispensations of risperidone (<jats:italic>n<\/jats:italic>\u00a0=\u00a038\u00a0211), other atypical antipsychotics not including paliperidone (<jats:italic>n<\/jats:italic>\u00a0=\u00a060\u00a0691), or typical antipsychotics (<jats:italic>n<\/jats:italic>\u00a0=\u00a017\u00a0445) within three months between 2006 and 2013. An osteoporosis\u2010related fracture was defined as a non\u2010open hip\/femur fracture in primary analyses. Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Risperidone users were on average older (mean age of 68, 44, and 63\u00a0years for risperidone, other atypical antipsychotics, and typical antipsychotics respectively). Compared with other atypical antipsychotics, there was no association between risperidone and osteoporosis\u2010related fractures in the overall (HR\u00a0=\u00a01.04, CI: 0.91\u20131.19) or age\u2010stratified analyses. A significantly increased risk of typical antipsychotics (HR\u00a0=\u00a01.24, CI: 1.07\u20131.45) compared with other atypical antipsychotics remained for ages &gt;45\u00a0years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Risperidone does not appear to be associated with an increased risk of osteoporosis\u2010related fracture compared with other atypical antipsychotic agents as a group. For typical antipsychotics, a moderately elevated risk of hip fractures was noted compared with other atypical antipsychotics, possibly because of residual confounding.<\/jats:p><\/jats:sec>","DOI":"10.1111\/acps.13101","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T15:39:47Z","timestamp":1569253187000},"page":"74-83","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Exposure to risperidone versus other antipsychotics and risk of osteoporosis\u2010related fractures: a population\u2010based study"],"prefix":"10.1111","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2354-6888","authenticated-orcid":false,"given":"E.","family":"Clapham","sequence":"first","affiliation":[{"name":"Centre for Pharmacoepidemiology (CPE) Department of Medicine Solna Karolinska University Hospital Karolinska Institutet Solna Sweden"},{"name":"Department of Neuroscience, Psychiatry Uppsala University Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bod\u00e9n","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology (CPE) Department of Medicine Solna Karolinska University Hospital Karolinska Institutet Solna Sweden"},{"name":"Department of Neuroscience, Psychiatry Uppsala University Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Reutfors","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology (CPE) Department of Medicine Solna Karolinska University Hospital Karolinska Institutet Solna Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Svensson","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology (CPE) Department of Medicine Solna Karolinska University Hospital Karolinska Institutet Solna Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ramcharran","sequence":"additional","affiliation":[{"name":"Janssen Global Research and Development Epidemiology Titusville NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Qiu","sequence":"additional","affiliation":[{"name":"Janssen Global Research and Development Epidemiology Titusville NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kieler","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology (CPE) Department of Medicine Solna Karolinska University Hospital Karolinska Institutet Solna Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bahmanyar","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology (CPE) Department of Medicine Solna Karolinska University Hospital Karolinska Institutet Solna Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107088439"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.1.64"},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/167138","article-title":"Osteoporosis associated with antipsychotic treatment in schizophrenia","volume":"2013","author":"Wu H","year":"2013","journal-title":"Int J Endocrinol."},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(02)00112-9"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1108"},{"key":"e_1_2_11_7_1","unstructured":"ErnstD.Warning Added to Antipsychotic Drug Labeling. Monthly Prescribing Reference;2017. Available from:http:\/\/www.empr.com\/safety-alerts-and-recalls\/antipsychotic-medication-warning-somnolence-hyoptension\/article\/640400\/[updated 2017 February 27 2017; cited 2017 May 3]."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1167873"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3881-3"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.04.002"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afw209"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S117321"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-009-9350-y"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"},{"key":"e_1_2_11_16_1","unstructured":"National Board of Health.D\u00f6dsorsaksstatistik: Historik produktionsmetoder och tillf\u00f6rlitlighet;2010. Available from:http:\/\/www.socialstyrelsen.se\/Lists\/Artikelkatalog\/Attachments\/18019\/2010-4-33.pdf[updated 2010; cited]."},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(85)80063-3"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-0962-6"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-010-0022-3"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.6930"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000647"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.05.017"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20458"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0438-8"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.5312\/wjo.v7.i3.171"},{"key":"e_1_2_11_26_1","first-page":"1371","article-title":"[Consumption of psychopharmaceuticals in residential facilities for the elderly. Evaluation of the extent, indications and effects]","volume":"98","author":"Nilsson L","year":"2001","journal-title":"Lakartidningen"},{"key":"e_1_2_11_27_1","unstructured":"Medical Products Agency.Risperidone. Summary of Product Characteristics;2016. Available from:https:\/\/docetp.mpa.se\/LMF\/Risperidon%20STADA%20film-coated%20tablet%20ENG%20SmPC.docx[updated 2016; cited March 18 2018]."},{"key":"e_1_2_11_28_1","unstructured":"National Board of Health.Prim\u00e4rv\u00e5rdens uppdrag;2016. Available from:https:\/\/www.socialstyrelsen.se\/Lists\/Artikelkatalog\/Attachments\/20066\/2016-3-2.pdf[updated 2016; cited]."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.3679"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Facps.13101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acps.13101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/acps.13101","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acps.13101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T02:59:49Z","timestamp":1694228389000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acps.13101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1111\/acps.13101"],"URL":"https:\/\/doi.org\/10.1111\/acps.13101","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]},"assertion":[{"value":"2019-09-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}